Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Adaptimmune Therapeutics PLC changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 92 | 1 | 85 | −6 |
| Shares | 111.7M | 58.8K | 113.6M | +1.97M (+1.8%) |
| Value | $577.3M | $304.0K | $425.9M | −$151.1M (−26.2%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Long Focus Capital Management, LLC | 2,162,313 | $8.11M | 2.21% |
| Syncona Portfolio Ltd | 1,377,294 | $5.17M | 4.93% |
| Renaissance Technologies LLC | 427,687 | $1.60M | 0.00% |
| Key Client Fiduciary Advisors, LLC | 256,048 | $960.0K | 0.80% |
| DAFNA Capital Management LLC | 136,266 | $511.0K | 0.13% |
| Jump Financial, LLC | 118,400 | $444.0K | 0.03% |
| CWM Advisors, LLC | 20,205 | $76.0K | 0.01% |
| XTX Topco Ltd | 17,560 | $66.0K | 0.04% |
| Inspire Advisors, LLC | 15,393 | $58.0K | 0.02% |
| Aigen Investment Management, LP | 11,776 | $43.0K | 0.00% |
| Hunter Associates Investment Management LLC | 11,000 | $41.0K | 0.01% |
| Chicago Partners Investment Group LLC | 12,265 | $38.0K | 0.00% |
| Blue Bell Private Wealth Management, LLC | 1,359 | $5.00K | 0.00% |
| High Net Worth Advisory Group LLC | 1,000 | $4.00K | 0.00% |
| Royal Bank of Canada | 84 | $0 | 0.00% |
Sold out (21)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Schonfeld Strategic Advisors LLC | 349,683 | $1.81M |
| Balyasny Asset Management LLC | 259,413 | $1.34M |
| Alps Advisors Inc | 190,550 | $985.0K |
| Vontobel Holding Ltd. | 103,000 | $533.0K |
| ExodusPoint Capital Management, LP | 86,202 | $446.0K |
| SG Americas Securities, LLC | 85,163 | $440.0K |
| AlphaCentric Advisors LLC | 68,500 | $354.0K |
| Healthcare of Ontario Pension Plan Trust Fund | 60,300 | $312.0K |
| Virtu Financial LLC | 47,542 | $246.0K |
| KBC Group NV | 45,900 | $237.0K |
| Susquehanna Fundamental Investments, LLC | 43,960 | $227.0K |
| DekaBank Deutsche Girozentrale | 42,000 | $215.0K |
| Blair William & Co | 40,000 | $207.0K |
| Trexquant Investment LP | 23,609 | $122.0K |
| MAI Capital Management | 12,534 | $65.0K |
| Blueshift Asset Management, LLC | 11,933 | $62.0K |
| Wealthspire Advisors, LLC | 11,750 | $61.0K |
| Toroso Investments, LLC | 10,554 | $55.0K |
| Brewin Dolphin Ltd | 7,050 | $36.4K |
| Penserra Capital Management LLC | 3,135 | $16.0K |
| Barclays PLC | 11 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 58,847 | $304.0K |